Objective:

To explore the analytical challenges and misconceptions in peptide therapeutics, particularly in the context of GLP-1 drugs.

Key Findings:

• Peptide therapeutics require more than pass/fail metrics; they demand detailed structural characterization.
• Conventional LC methods may not adequately resolve or identify peptide variants.
• Analytical workflows must include high-resolution mass spectrometry and ultra-high-performance liquid chromatography.
• Routine QC methods need to be robust and efficient while still providing meaningful data on critical quality attributes.

Interpretation:

The shift in peptide analytics is from a focus on purity to an emphasis on understanding structural microheterogeneity.

Limitations:

• The article does not provide specific case studies or quantitative data to support claims.
• It lacks a detailed exploration of the regulatory implications of the discussed analytical methods.

Conclusion:

Peptide analysis is evolving, necessitating advanced analytical strategies to ensure the quality and efficacy of peptide therapeutics.